Journals / Selçuk Tıp Dergisi / 2021 / Cilt: 37 - Sayı: 2

Comparison of The Two Lipoprotein Apheresis Methods in The Treatment of Familial Hypercholesterolemia

Familial Hiperkolesterolemi T edavisinde İki Lipoprotein Aferezi Yönteminin Karşılaştırılması

Pages
118–123
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: In conclusion, our study suggests that it would be more appropriate to choose the apheresis method according to the clinical and laboratory findings of the patient since it shows that two different methods have different effects on serum electrolyte values, hemostasis criteria and leukocyte and platelet counts.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Familial hypercholesterolemia (FH) is an autosomal dominant inherited genetic disorder that causes a significant increase in low-density lipoprotein (LDL) cholesterol levels and leads to early coronary heart disease and cardiac mortality.
📊
Key Findings & Data:Although this disease has a heterozygous (HeFH) and homozygous (HoFH) form, the incidence of HeFH is reported to be 1: 500, while HoFH is reported to be 1: 1 000 000.
💡
Conclusion & Impact:Conclusions: In conclusion, our study suggests that it would be more appropriate to choose the apheresis method according to the clinical and laboratory findings of the patient since it shows that two different methods have different effects on serum electrolyte values, hemostasis criteria and leukocyte and platelet counts.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant inherited genetic disorder that causes a significant increase in low-density lipoprotein (LDL) cholesterol levels and leads to early coronary heart disease and cardiac mortality. Although this disease has a heterozygous (HeFH) and homozygous (HoFH) form, the incidence of HeFH is reported to be 1: 500, while HoFH is reported to be 1: 1 000 000. This disease is often caused by LDL receptor (most common), apolipoprotein B (Apo B), Proprotein Convertase Subtilisin/Kexin 9 (PCSK9), and LDL receptor adaptor protein (LDLRAP) gene mutations. Patients with FH do not respond well to lipid-lowering therapies such as a statin, and so lipoprotein apheresis is the treatment of choice. Patients and Methods: We compared the results of lipoprotein apheresis in a 20-year-old female patient diagnosed with HoFH with two different methods [double-filtration plasmapheresis (DFPP) and dextran sulfate column (DSC) methods]. 40 lipoprotein apheresis procedures including 20 sessions of DFPP and 20 sessions of DSC were evaluated. Results: When the two methods were compared the changes in high-density lipoprotein, white blood cells, platelets, potassium, calcium, prothrombin time (INR) and activated partial thromboplastin time values were statistically significant. Conclusions: In conclusion, our study suggests that it would be more appropriate to choose the apheresis method according to the clinical and laboratory findings of the patient since it shows that two different methods have different effects on serum electrolyte values, hemostasis criteria and leukocyte and platelet counts.

Özet

Ailesel hiperkolesterolemi düşük dansiteli lipoprotein kolesterol düzeyinin önemli derecede yükselmesine ve erken yaşta koroner arter hastalığı ile kalp nedenli ölüme yol açan otozomal dominant kalıtımlı bir genetik hastalıktır. Bu hastalığın heterozigot ve homozigot formları vardır ve insidansları sırasıyla 1:500 ve 1:1 000 000 olarak rapor edilmiştir. Bu hastalık sıklıkla LDL reseptörü (en sık), apolipoprotein B (Apo B), proprotein konvertaz subtilisin/cexin 9 (PCSK9) ve LDL reseptör adaptör proteini (LDLRAP) gen mutasyonları nedeniyle ortaya çıkmaktadır. Ailesel hiperkolesterolemili hastalar statin gibi lipid-düşürücü tedavilere iyi yanıt vermez ve bu nedenle lipopr otein aferezi seçkin tedavi yöntemidir . Hastalar ve Yöntem: Homozigot ailesel hiperkolesterolemi tanısı alan 20 yaşında kadın hastada, çift filtrasyon plazmaferez (DFPP) ve dekstran sülfat kolonu (DSC) olmak üzere farklı iki lipoprotein aferez yönteminin sonuçlarını karşılaştırdık. 20 seans çift filtrasyon plazmaferez (DFPP) ve 20 seans dekstran sülfat kolonu (DSC), toplam 40 aferez seansı değerlendirildi. Bulgular: İki yöntemin karşılaştırılmasında, yüksek dansiteli lipoprotein (YDL), lökosit, platelet, potasyum, kalsiyum, protrombin zamanı ve aktive parsiyel tromboplastin zamanı değerleri değişiklikleri istatistiksel olarak anlamlı bulundu. Sonuç: Sonuç olarak, çalışmamız iki farklı yöntemin serum elektrolit değerleri, hemostaz ölçütleri ve lökosit, trombosit sayılarına farklı etkileri olduğunu gösterdiği için, aferez yöntemi seçiminin hastanın klinik ve laboratuvar bulgularına göre yapılmasının daha uygun olacağını düşündürmektedir.

🔖

Cite This Article

Karaselek, M. A., Kulaksizoglu, M., Ceneli, O., Tekinalp, A., Demircioglu, S. (2022). Comparison of The Two Lipoprotein Apheresis Methods in The Treatment of Familial Hypercholesterolemia. Selçuk Tıp Dergisi, Cilt: 37 - Sayı: 2, 118–123. https://ajindex.com/articles/591806

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Schuff-Werner P, Gohlke H, Bartmann U, et al. The HELPLDL- apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24(11):724-32.
  2. Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin 2015;33(2):169-79.
  3. Whitfield AJ, Barrett PHR, van Bockxmeer FM, et al. Lipid disorders and mutations in the APOB gene. Clin Chem 2004; 50(10):1725-32.
  4. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. The Journal of Lipid Research 2009;50:172-7.
  5. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232 (4746):34-47.
  6. Goldstein JL, Hobbs HH, Brown MS. The metabolic and molecular basis of inherited disease. New York: McGraw Hill, 2001.
  7. Schöb M, Müller P, Gerth YY, et al. Diagnosis and treatment of familial hypercholesterolemia. Praxis 2018;107(24):1345- 53. Makino H, Tamanaha T, Harad a-Shiba M. LDL apheresis in Japan. Transfus Apher Sci 2017; 56(5):677-81.
  8. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidencebased approach from the writing committee of the american society for apheresis: The Seventh Special Issue. J Clin Apher 2016;31(3):149-62.
  9. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-07.
  10. Nordestgaard B, Chapman M, Humphries S. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinician stop revent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013;34(45):3478-90a. Cuchel M, Bruckert E, Ginsberg H. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. Eur Heart J 2014;35(32):2146-57.
  11. Wang A, Richhariya A, Gandra SR, et al. Systematic review of low density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc 2016;5(7):e003294. Otto C, Kern P, Bambauer R, et al. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif O